Abstract: Novel derivatives of rapamycin, particularly 9-deoxo-rapamycins, 26-dihydro-rapamycins, and 40-O-substituted and 28,40-O,O-disubstituted rapamycins. are found to have pharmaceutical utility, particularly as immunosuppressants.

Abstract: Biologically active, pure neutrophil-activating factor (NAF) isolated from human monocytes or after expression of a synthetic NAF gene in E.coli and having the following amino acid sequence Ser-Ala-Lys-Glu-Leu-Arg-Cys-Gln-Cys-Ile-Lys-Thr-Tyr-Ser-Lys-Pro-Phe-His-Pro-Lys-Phe-Ile-Lys-Glu-Leu-Arg-Val-Ile-Glu-Ser-Gly-Pro-His-Cys-Ala-Asn-Thr-Glu-Ile-Ile-Val-Lys-Leu-Ser-Asp-Gly-Arg-Glu-Leu-Cys-Leu-Asp-Pro-Lys-Glu-Asn-Trp-Val-Gln-Arg-Val-Val-Glu-Lys-Phe-Leu-Lys-ArgAla-Glu-Asn-Ser.

Abstract: Proteins expressed in NK and some T cells and being transmembrane molecules with Type II membrane protein structure, the extracellular part of the receptor being characterized by a C-type animal lectin domain, DNA sequences encoding such proteins and antibodies against the extracellular part of the transmembrane protein which can activate NK and T cells.

Abstract: Compounds of formula I ##STR1## wherein A, B, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description, are useful for the treatment of conditions where prevention or delay of progressive atrophy of the optic nerve is desirable.

Abstract: Wood preserving composition comprising a compound of formula I ##STR1## wherein A is selected from ##STR2## whereby the .beta.-carbon attaches to benzene ring of formula (I); R.sub.1 and R.sub.2 are independently H or Cl;R.sub.3 and R.sub.4 are independently R or CH.sub.3 ; andR.sub.5 is methyl, ethyl or cyclopropyland method for preserving wood with the aid of a compound of formula (I).

Abstract: A new process is described for the production of 6-alpha-amino-penicillins and 7-alpha-amino-desacetoxy-cephalosporins free from halogen-containing solvents by acylating 6-APA, 7-ADCA or a derivative thereof in a halogen-free solvent.

Abstract: The nucleotide sequence which codes for cyclosporin synthetase and similar enzymes and recombinant vectors containing the sequence. The vectors are used in methods for the production of cyclosporin and cyclosporin derivatives.

Abstract: Peptides having the amino acid sequence ##STR1## wherein X is H, Asp-Leu-Tyr-, Ser-Asp-Leu-Tyr- or Asp-Ser-Asp-Leu-Tyr-. The peptide wherein X is H is human neutrophil-activating peptide-2 (hNAP-2) and those wherein X is other than H are natural variants thereof. The peptides have neutrophil-stimulating activity, are structurally related to NAF/NAP-1, .beta.-thromboglobulin, PBP and CTAP-III and may be isolated from leukocytes and platelets and synthesized by standard peptide synthesis processes and recombinant DNA techniques.

Abstract: Plaster formulations of agricultural and pest control chemicals which form slow release briquets in situ.

Abstract: Complexes of formulae I and II ##STR1## wherein the variables are as defined in the specification are useful as dyes for, for example, the mass dyeing of plastics and for lacquers.

Abstract: Pulmonary administration of Ciclosporin in orthorhombic crystal form (designated "CY-A/X-III"), e.g. for the treatment of obstructive or inflammatory airways disease, e.g. asthma, as well as crystalline Ciclosporin, e.g. CY-A/X-III, in spheroidal particulate form, processes for its preparation and its pharmaceutical use, e.g. for pulmonary administration. Pharmaceutical compositions comprising CY-A/X-III and crystalline Ciclosporin, e.g. CY-A/X-III, in spheroidal particulate form as well as Ciclosporin in solution in aerosol propellants are also provided.

Abstract: A new process is described for the production of 6-alpha-amino-penicillins and 7-alpha-amino-desacetoxy-cephalosporins free from halogen-containing solvents by acylating 6-APA, 7-ADCA or a derivative thereof in a halogen-free solvent.

Abstract: A biologically active peptide selected from growth factors, peptide hormones, interferons and cytokines and analogues and derivatives thereof, and bearing at least one chelating group linked to an amino group of said peptide, the chelating group being capable of complexing a detectable element and such amino group having no significant binding affinity to target receptors, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of target tissues or for therapy.

Abstract: Compounds of the formula ##STR1## wherein R, R.sub.1 and R.sub.2 are as defined in the specification and R.sub.3 is amino or --N.dbd.N--K, wherein K is a coupling component radical. The compounds wherein R.sub.3 is --N.dbd.N--K are useful as disperse dyes, and those wherein it is amino are useful as intermediates in the synthesis of those wherein it is --N.dbd.N--K.

Abstract: A process for the production of a dry pancreatin preparation is characterized in that the still moist pancreatin mass, which is obtained after extraction with a solvent or solvent mixture, is treated, before the solvents are finally removed, for a short time in a vacuum cutter, until the mass has been divided and shaped into small spherical particles, and then is finally dried.

Abstract: Compounds of the formula ##STR1## iron complexes thereof and mixtures of such iron complexes, wherein D is a monocyclic or bicyclic aromatic diazo component radical of the benzene series containing one --SO.sub.3 M group or is ##STR2## R.sub.1 is hydrogen, methyl or ethyl, and R.sub.4 is hydrogen, chloro or C.sub.1-2 alkyl,wherein R' is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl, methoxy(C.sub.2-4 alkyl) or ##STR3## R" is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl or methoxy(C.sub.2-4 alkyl), or--NR'R" is a saturated 5- or 6-membered ring,R.sub.5 is hydrogen, chloro or C.sub.1-2 alkyl, andX is hydrogen or hydroxy,wherein each R.sub.2 is independently hydrogen, chloro, hydroxy, C.sub.1-2 alkyl, C.sub.1-2 alkoxy or --SO.sub.2 NR.sub.o R.sub.o, andeach R.sub.3 is independently hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, --COOM, trifluoromethyl or --NR"'R"",wherein each R"' and R"" is independently C.sub.1-4 alkyl, C.sub.2-4 hydroxyalkyl, methoxy(C.sub.2-4 alkyl) or carbamoyl(C.sub.

Abstract: Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.

Abstract: The compounds of formula I, ##STR1## have been found to have excellent topical activity. They are thus indicated for use in the topical treatment of inflammatory and hyperpoliferative skin diseases and of cutaneous manifestations of immunologically-induced illnesses, such as psoriasis.

Abstract: A p-toluenesulphonic acid salt of 7-[2-(2-aminothiazol-4-yl)-2-(Z)-hydroximino-acetamido]-3-N,N-dimethylcarb amoyloxymethyl-3-cephem-4-carboxylic acid (isopropoxycarbonyloxy)ethylester, e.g. of formula ##STR1## its use in the production of other salts and a pharmaceutical composition containing it.

Abstract: The present invention provides a sugar derivative of a biologically active peptide, which derivative has a prolonged duration of action when compared to the non-sugar modified peptide, and contains at least on one of the amino acid units a sugar residue which is attached to an amino group thereof by a coupling other than a direct N-glycosidic bond, and additionally, when it is a condensation product of a carboxyl group containing sugar and a peptide with less than 8 amino acid units, by a coupling other than a direct amide bond.